Bevacizumab in metastatic breast cancer: when may it be used?
Explore this paper's citation graph
Summary
The addition of bevacizumab to chemotherapy has improved progression-free survival in the first- and second-line treatment of patients with advanced-stage breast cancer.
- Type
- article
- Published
- 2011-03-01
- Cited by
- 18
- References
- 40
- Access
- Open access
- OpenAlex
- https://openalex.org/W2076763691
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:206797811
Keywords
Bevacizumab, Medicine, Metastatic breast cancer, Angiogenesis, Breast cancer
References
- RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer.
- Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer.
- Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol.
- A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC).
- Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment.
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- Estrogen regulates vascular endothelial growth/permeability factor expression in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors.
- RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer.
- Systemic Therapy of Advanced Breast Cancer
- Final Overall Survival (OS) Results from the Randomised, Double-Blind, Placebo-Controlled, Phase III AVADO Study of Bevacizumab (BV) Plus Docetaxel (D) Compared with Placebo (PL) Plus D for the First-Line Treatment of Locally Recurrent (LR) or Metastatic Breast Cancer (mBC).
- Chromatin immunoprecipitation analysis of gene expression in the rat uterus in vivo: estrogen-induced recruitment of both estrogen receptor alpha and hypoxia-inducible factor 1 to the vascular endothelial growth factor promoter.
- Abstract P2-16-03: Sorafenib in Combination with Paclitaxel as a First-Line Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer: Overall Survival Results from a Double-Blind, Randomized, Placebo-Controlled, Phase 2b Trial
- SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer (BC).
- Preliminary safety results from a multicenter phase II noncomparative two arm pilot of bevacizumab with anastrozole or fulvestrant as 1stline metastatic breast cancer therapy.
- Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model.
- A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.
- Safety of bevacizumab (BV) plus docetaxel (D) in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) who developed brain metastases during the AVADO phase III study.
- Estrogen and Angiogenesis: A Review
- In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer
- Acute temporal regulation of vascular endothelial growth/permeability factor expression and endothelial morphology in the baboon endometrium by ovarian steroids.
Cited by
- Vascular endothelial growth factor (VEGF) - part 2: in endocrinology and oncology.
- Antiangiogenic therapy of breast cancer. How did we get here? The road not taken
- Recent advances in the application of antibodies as therapeutics.
- In vitro the behaviors of metastasis with suppression of VEGF in human bone metastatic LNCaP-derivative C4-2B prostate cancer cell line
- Anti-angiogenesis therapy and gap junction inhibition reduce MDA-MB-231 breast cancer cell invasion and metastasis in vitro and in vivo
- Bevacizumab in the 1st line treatment of triple negative metastatic breast cancer patient — case report and review of the literature
- [Vascular endothelial growth factor (VEGF) in endocrinology and oncology].
- Inhibition of VEGF and Angiopoietin-2 to Reduce Brain Metastases of Breast Cancer Burden
- A new immunotherapy schedule in addition to first-line hormone therapy for metastatic breast cancer patients in a state of clinical benefit during hormone therapy
- Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy
- A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.
- Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review
- Monoclonal antibodies in breast cancer: a critical appraisal.
- Decellularized plant-derived vasculature-on-a-chip interacting with breast cancer spheroids to evaluate a dual-drug therapy
- Amelioration of breast cancer therapies through normalization of tumor vessels and microenvironment: paradigm shift to improve drug perfusion and nanocarrier permeation
- The Role of Osteoprotegerin in Breast Cancer: Genetic Variations, Tumorigenic Pathways, and Therapeutic Potential
- Targeting focal adhesion kinase inhibits cell migration and non-angiogenic vascularization in malignant breast cancer
- Vascular endothelial growth factor (VEGF) — part 2: in endocrinology and oncology Naczyniowo-śródbłonkowy czynnik wzrostu (VEGF) — część 2: w endokrynologii i onkologii
Related papers
- Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials
- Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe?
- Plasma vascular endothelial growth factor as a predictive biomarker: Door closed?
- First-line Treatment of Metastatic Breast Cancer: Focus on Bevacizumab:
- Review of bevacizumab in the treatment of metastatic breast cancer
- Comparison of Serum Concentrations of Bevacizumab and Vascular Endothelial Growth Factor (VEGF) Levels in Laser and Bevacizumab Treated ROP Patients
- Expression of total vascular endothelial growth factor (VEGF) and inhibitory isoforms of VEGF in head and neck squamous cell carcinoma